Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement
Pathology and Oncology Research · 2023
DOI: 10.3389/pore.2023.1611250 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pathology and Oncology Research, 2023. Verfasst von Andrea Ceglédi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Saint…. Hauptthemen laut MEDLINE: Factor V, Cesarean Section. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Acquired factor V inhibitor (AFVI) is a rare autoimmune bleeding disorder. The treatment of AFVI is challenging, and patients often require both bleeding control and inhibitor eradication.
Methods
We conducted a retrospective analysis of the medical records of a 35-year-old Caucasian woman who presented with severe AFVI-induced bleeding and subsequent immunosuppressive therapy.
Results
To provide haemostasis, rFVIIa was given with good efficacy. The patient was treated with various combinations of immunosuppressive regimens over the course of 2.5 years, including plasmapheresis plus immunoglobulins, dexamethasone + rituximab, cyclophosphamide + dexamethasone + rituximab + cyclosporine, cyclosporin + sirolimus + cyclophosphamide + dexamethasone, bortezomib + sirolimus + methylprednisolone, and sirolimus + mycophenolate mofetil. Although these treatment modalities resulted in intermittent partial reversals of AFVI over 2.5 years, eventually the inhibitor became therapy-resistant. However, following the discontinuation of all immunosuppressive therapy, the patient experienced a partial spontaneous remission, which was followed by a pregnancy. During the pregnancy, the FV activity increased to 54% and the coagulation parameters returned to normal levels. The patient underwent Caesarean section without any bleeding complications and delivered a healthy child.
Discussion
The use of an activated bypassing agent for bleeding control is effective in patients with severe AFVI. The presented case is unique because the treatment regimens included multiple combinations of immunosuppressive agents. This demonstrates that AFVI patients may undergo spontaneous remission even after multiple courses of ineffective immunosuppressive protocols. Additionally, pregnancy-associated improvement of AFVI is an important finding that warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Saint Ladislaus Campus, Budapest, Hungary.
- Department of Public Health, Semmelweis University, Budapest, Hungary.
- Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States.
Zitieren
APA
Ceglédi, A., Dolgos, J., Fekete, M., Gopcsa, L., Várkonyi, A., Vilimi, B., Mikala, G., & Bodó, I. (2023). Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement. Pathology and Oncology Research. https://doi.org/10.3389/pore.2023.1611250
Vancouver
Ceglédi A, Dolgos J, Fekete M, Gopcsa L, Várkonyi A, Vilimi B, et al. Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement. Pathology and Oncology Research. 2023. doi:10.3389/pore.2023.1611250
BibTeX
@article{Cegldi2023,
author = {Ceglédi, Andrea and Dolgos, János and Fekete, Mónika and Gopcsa, László and Várkonyi, Andrea and Vilimi, Beáta and Mikala, Gábor and Bodó, Imre},
title = {Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement},
journal = {Pathology and Oncology Research},
year = {2023},
doi = {10.3389/pore.2023.1611250}
}
EUVIMED